Fundraising Overview - The company successfully raised a net amount of RMB 26,911.62 million after deducting issuance costs from the initial public offering of 21,666,668 shares [1] - The funds have been fully received and verified by Tianzhi International Accounting Firm [1] Fund Management and Usage - The company has established a special account for the management and storage of the raised funds, in compliance with relevant regulations and internal management policies [1] - A tripartite supervision agreement has been signed with the sponsoring institution and the bank to ensure proper management of the funds [1] Fund Account Status - The company has detailed the status of its fundraising special accounts, including various projects such as online marketing network construction, offline service network upgrades, and research center construction [1] - Specific accounts have been opened at banks like Ping An Bank and Industrial and Commercial Bank of China for different projects [1] Account Cancellation - The company has canceled a fundraising special account with a balance of RMB 3,962.27, transferring the remaining funds to its general account for daily operational liquidity [2] - The cancellation of the account has been completed, and the corresponding regulatory agreement has also been terminated [2]

Core Viewpoint - A research team from the University of Washington and the Brotman Baty Institute has developed a "claw machine"-like technology for the rapid and automated classification of embryoid bodies, providing critical support for studying individual differences in early embryonic development and the mechanisms of genetic diseases [1][2]. Group 1: Technology Development - The newly developed automated sorting system integrates microscopy, cameras, and robotic micro-manipulation technology, featuring a detachable micro-structure called "micro-raft" for the growth of embryoid bodies [2]. - The system operates like a high-precision "claw machine," autonomously scanning large arrays of "micro-rafts," identifying the characteristics of embryoid bodies, and physically sorting them based on preset criteria, enhancing precision and efficiency [2]. Group 2: Research Implications - The embryoid body model can reveal early developmental abnormalities similar to human diseases, previously clarifying how Huntington's disease manifests genetic traits in early embryos, even before traditional clinical symptoms appear [2]. - The new platform can sort unique embryoid bodies exhibiting subtle phenotypic differences, maintaining sample integrity and paving the way for subsequent live-cell imaging or genetic sequencing [2].

Group 1 - Suzhou is enhancing its employment-friendly city construction to promote high-quality development and employment expansion, having been recognized as the best city for employment promotion for five consecutive years [1] - The city has established 348 local employment service stations, helping over 9,000 individuals from disadvantaged groups find jobs [2] - The local government is focusing on providing precise employment services, including matching job seekers with local recruitment needs and offering free accommodation for out-of-town job seekers [2] Group 2 - Major projects in Suzhou are expected to create over 30,000 new jobs, with more than 200 significant projects being completed since the beginning of 2024 [4] - The city is integrating industry, education, and research to enhance employment opportunities along the industrial chain, including the development of a low-altitude economy and tailored skill training programs [4] - A new training model combining job needs, skill training, and employment services is being implemented to cultivate skilled workers in emerging sectors like drone technology [4][6] Group 3 - Suzhou is launching a summer skill training program to utilize the teaching downtime in schools, aiming to enhance the practical skills of young individuals [6] - The focus on improving employment skills is seen as essential for maintaining the dynamism of the local economy and ensuring the continuous evolution of industry and talent [6]

Group 1: Event Overview - The 11th China (Shanghai) International Technology Import and Export Fair was held from June 11 to June 13, focusing on "hard technology" and future industries, showcasing nearly a hundred breakthrough achievements in fields like brain-machine interfaces, embodied intelligence, quantum technology, and synthetic biology [1][2] - The event highlighted significant innovations such as the world's first sound tweezers single-cell sorting technology and the debut of self-developed lunar soil fiber technology and equipment, indicating a promising future for the technology industry [1][2] Group 2: Innovations in Lunar Technology - East China University of Science and Technology showcased the "in-situ preparation of lunar soil fiber modular equipment," which is included in China's lunar base construction plan, utilizing lunar soil from the Chang'e 5 mission to create fibers for lunar base construction [2] - The technology aims to convert lunar soil into high-performance fibers, enabling local resource utilization and meeting the material performance needs for lunar base construction [2] Group 3: Advancements in Biotechnology - The Soundpen CB system developed by Oubino Biotechnology employs non-contact, label-free acoustic tweezers to manipulate cells with precision, significantly enhancing experimental efficiency by minimizing cell damage [3] - The event also featured brain-machine interface technologies that allow patients with central nervous system injuries to control exoskeletons for rehabilitation, demonstrating practical applications in hospitals and rehabilitation centers [5][6] Group 4: Robotics and Automation - The fair showcased various robots, including a six-legged robot designed for Antarctic research, which can assist in transporting materials and ensuring safety by detecting cracks in the ice [3][4] - Nanjing University presented a multimodal interactive robot capable of intelligent dialogue and music synchronization, which is already in mass production and available in North America [4] Group 5: 3D Printing in Pharmaceuticals - The company San Diego demonstrated its 3D printing technology for pharmaceuticals, achieving continuous and large-scale production of printed drugs, with an annual capacity of 75 million to 300 million tablets [6] - Lepu Medical introduced the MemoSorb biodegradable occluder series, the first of its kind globally, providing innovative treatment solutions for congenital heart disease and stroke prevention [6]

就A股市场来看，A股上半年共有50家企业实现首发上市，上 市企业以中小规模企业为主，合计筹资超过371亿元，IPO数 量和筹资额实现双增长，均同比上升14%。 作者：姜鑫 封图：图虫创意 "2025上半年，未有IPO破发，IPO平均首日回报达到220%，与2024上半年的136%相比，同比大幅上升。" 2025年6月12日，在《中国内地和香港IPO市场》报告（下称"报告"）发布现场，安永北京主管合伙人杨淑娟如是介绍了上半年A股IPO（首次公开募 股）发行情况。 报告显示，2025年上半年，中国内地和香港地区IPO活动在全球中的占比上升。其中，香港IPO活动表现抢眼，筹资额占全球总筹资额的24%，与A股 合计占全球总筹资额的33%。同时，得益于宁德时代等大型IPO推动，港交所以140亿美元募资规模登顶全球。 全球市场IPO数量和融资规模 A股IPO平均首日回报达到220% 就A股市场来看，A股上半年共有50家企业实现首发上市，上市企业以中小规模企业为主，合计筹资超过371亿元，IPO数量和筹资额实现双增长，均同 比上升14%。 报告显示，从行业来看，工业、科技和材料领域的IPO数量和筹资额分居前三位。汽车行业作 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-039 北京百普赛斯生物科技股份有限公司 监事会关于公司 2025 年股权激励计划授予激励对象名单（授予 日）的核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届监事会第十 七次会议于 2025 年 6 月 12 日在公司会议室召开，审议通过了《关于向 2025 年 限制性股票激励计划激励对象首次授予限制性股票的议案》《关于向 2025 年股 票增值权激励计划激励对象授予股票增值权的议案》。 公司监事会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办 法》（以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以 下简称"《上市规则》"）等有关法律、法规和规范性文件的规定，对获授权益的 激励对象名单进行审核，发表核查意见如下： 本次授予的激励对象具备《公司法》《证券法》等法律、法规和规范性文件 以及《公司章程》规定的任职资格，符合《管理 ...

Group 1 - The company held its 17th meeting of the second supervisory board on June 12, 2025, with all supervisors agreeing to waive the notification time limit for the meeting [1] - The supervisory board unanimously approved the proposal for the initial grant of restricted stock under the 2025 Restricted Stock Incentive Plan, with the grant date set for June 12, 2025, and the grant price at 25.44 yuan per share [2][3] - The supervisory board also approved the proposal to grant stock appreciation rights to 31 eligible incentive objects under the 2025 Stock Appreciation Rights Incentive Plan, with a total of 251,900 stock appreciation rights granted at an exercise price of 25.44 yuan per right [3] Group 2 - The supervisory board confirmed that the incentive objects meet the qualifications stipulated in relevant laws, regulations, and the company's articles of association, ensuring the legality and validity of the incentive plan [2][3] - The decisions made during the meeting were in accordance with the company's 2025 incentive plans approved by the shareholders' meeting [2][3]

德国经济部：我们原则上支持德国生物科技公司BioNTech和CureVac的交易。 ...

Core Viewpoint - The company plans to transfer the income rights of 9.79% of shares in Longli Biological to Shandong Jinzi for 4.3962 million yuan, while also entrusting the corresponding voting rights to Shandong Jinzi, constituting a related party transaction [2][3][10]. Summary by Sections Related Party Transaction Overview - Shandong Gaoxin Investment intends to transfer the income rights of its 9.79% stake in Longli Biological to Shandong Jinzi, a subsidiary of its controlling shareholder, Shandong Lixin Investment Holding Group [2][3]. - The transaction requires approval from the company's shareholders' meeting, with related shareholders abstaining from voting [3][12]. Related Party Introduction - Lixin Group holds 69.57% of the company's A shares, while Shandong Jinzi is a subsidiary of Lixin Group [2][3]. - As of March 31, 2025, Shandong Jinzi reported total assets of 1139.44 billion yuan and net assets of 70.186 billion yuan [4]. Transaction Target Overview - The target asset is the income rights of 58,722,408 shares in Longli Biological, which has been suspended from trading since May 2022 [4][5]. - The shares are free from any encumbrances or legal disputes [4]. Financial Information of the Transaction Target - Longli Biological reported total assets of 478.272 million yuan and a net asset deficit of 583.18739 million yuan as of December 31, 2024 [5]. - The company has faced consecutive years of audit reports with disclaimers since 2017, affecting the valuation of its equity [5]. Pricing of the Transaction - The transfer price of 4.3962 million yuan was determined based on pre-suspension prices and the company's restructuring plan, considering asset risks and liquidity [5][6]. Agreement Details - The transaction involves signing a "Share Income Rights Transfer Agreement" and a "Voting Rights Entrustment Agreement" between Shandong Gaoxin Investment and Shandong Jinzi [6][10]. - The income rights transferred include all cash income and property rights derived from the shares [7][8]. Impact of the Transaction on the Company - The transaction is expected to help reduce the company's non-performing asset ratio and aligns with its long-term development strategy [10][11]. - After the transaction, the company anticipates an increase in investment income of approximately 15.7831 million yuan [11]. Approval Process for the Transaction - The board of directors has approved the transaction, which will be submitted for shareholder approval, with related parties abstaining from voting [12][13].

证券代码：688289 证券简称：圣湘生物 公告编号：2025-039 圣湘生物科技股份有限公司 关于受让湖南圣维斯睿生物科技有限公司部分股 权暨与关联方共同投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）拟以自有资金人 民币 500 万元的对价受让 SEPSET BIOSCIENCES, INC.（以下简称"SEPSET"）所 持有的湖南圣维斯睿生物科技有限公司（以下简称"圣维斯睿"）10%股权（对应注 册资本人民币 500 万元，已实缴）。 ? 圣维斯睿的原股东中包括公司关联方湖南湘江圣湘生物产业基金合伙企业 （有限合伙）（以下简称"产业基金"），本次交易构成与关联方共同投资，未构成 《上市公司重大资产重组管理办法》规定的重大资产重组。 ? 本次交易实施不存在重大法律障碍。 票上市规则》（以下简称"《上市规则》"）的规定，本次交易构成与关联方共同投资， 具体参见"二、关联人及股权转让方基本情况"之"（一）关联关系说明"。 截至本次 ...